Geron Corp licensed its cancer compound, the last in its pipeline, to a unit of Johnson & Johnson for up to $935 million, sending its shares up as much as 33 percent in extended trading.
Breaking News
Subscribe to VCpost newsletter
Most Popular
- Former CEO Shoots Himself to Commit Suicide After Receiving $25 Million Record-Breaking Fine for Fraud at Steinhoff
- Xi Jinping Warns Dutch PM That 'No Force' Can Stop China's Technological Advancement Amid Export Restrictions
- Businessman Brutally Murdered Allegedly by 4 of His Workers Who Swung an Axe Into His Head
- Taylor Swift Reaches Her Billionaire' Era,' Joining Elon Musk and Jeff Bezos on the List of World's Wealthiest People
- Four Deaths May Be Linked to Dietary Supplements Made by Japan’s Kobayashi Pharmaceutical: Report
- Major AI Companies Unite to Create the World's First Artificial Superintelligence Alliance Worth $7.6 Billion
- Disney Investor Nelson Peltz Criticizes the Company’s 'Woke' Strategy, Questioning 'Black Panther' and 'The Marvels' Films
- Alaska Airlines Passenger Loses Pet Dog During Loading Due to Airline Misstep